Press release, Helsinki, 14 september 2017 there is a 19.00
Increase of the share capital of Nexstim Plc shares subscribed for the stock options 2013A
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “company“), a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic and diagnostic applications announces for the subscription of 110,000 new shares in Nexstim Plc stock options 2013A. Tekningspriset for the new shares, a total of 1100 euros, will be recorded as equity unrestricted equity, and the new shares will be entered in the trade register approximately on 19 september 2017. The new shares are admitted to trading on Nasdaq First North Finland and Nasdaq First North Sweden is estimated to 20 september 2017. After the new shares have been registered, the total number of registered shares in the company to 86 163 694.
Nexstim Plc holds 772 268 subscription rights in aktieoptionsprogrammen 2016 and 2013A. The outstanding stock options 2013A entitles the holder to subscribe for a maximum of 199 792 shares at a price of 0.01 euro per share. The subscription period expires on 15 december 2025 for option 2016 and 31 december 2020 for stock option 2013A.
Martin Jamieson, executive director
For more information go check on the company’s website at
Martin Jamieson, executive director +44 77 1516 3942
UB Securities Oy (Certified Adviser) +358 (0)9 2538 02 46
Citigate Dewe Rogerson +44 (0)207 2822949
David Dible/Shabnam Bashir/Isabelle Andrews email@example.com
About Nexstim Plc
Nexstim is a medical device company that developed and markets a ground-breaking system to navigate a non-invasive brain stimulation for therapeutic applications (NBT®system) and diagnostic applications (NBS-system). Nexstims NBS system is the first and only FDA-approved and CE-marked system to navigate transcranial magnetic stimulation (navigated Transcranial Magnetic Stimulation, nTMS) for mapping of the areas of motor skills and speech in the brain before a surgical procedure. On the same technology platform the company has developed a system to navigate hjärnterapi (Navigated Brain Therapy, NBT®), which has received CE marking in Europe for the treatment of stroke, severe depression and chronic neuropathic pain.
Nexstim recently applied on the 510(k) approval with the FDA for the use of the NBT®system for the treatment of major depressive disorder (MDD). Nexstim looking forward to the launch of the NBT®system for this important indication in the beginning of 2018. The NBT®system is currently undergoing additional Phase III trials (E-FIT) with 60 patients. Nexstim expects the trial ends the second quarter of 2018 and that the company then can request for authorization from the FDA. With the approval from the FDA would Nexstim able to begin marketing and selling the NBT®system for the treatment of stroke in the united states.
Nexstims shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. More information is available at www.nexstim.com.
Increase of the share capital
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire